THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company
developing Tcelna®, a novel T-cell immunotherapy for the
treatment of multiple sclerosis (MS), today announced that the Company
has been featured in Neurology Reviews. The article, titled "Regulation
May Be Impaired in Patients With Secondary Progressive MS,” was
written by Erik Greb, the publication's senior associate editor, and
presents data from Opexa’s Immune Monitoring program that is part of its
ongoing Phase IIb Abili-T trial in Secondary Progressive MS (SPMS).
The article presents baseline data on Opexa’s Immune Monitoring Program
that was previously presented at the 2013 Americas Committee for
Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting. The
immune monitoring data will be used to assess the impact of Tcelna in
SPMS patients compared to patients receiving placebo. Opexa’s data
supports the finding that immune regulation appears to be impaired in
individuals with SPMS. Opexa characterized the status of patients with
SPMS entering the Phase IIb trial at baseline and compared the data sets
to those of healthy donors. The results showed a marked difference
between key biomarkers of inflammation, specifically TR1 and Treg cells,
in patients suffering from SPMS versus healthy donors. The results
corroborated findings in the literature and provide support for the
assays being utilized by Opexa for the immune monitoring program.
“As part of our Phase IIb Abili-T trial, we are undertaking a
comprehensive immune monitoring program for all patients enrolled in the
study,” commented Donald Healey, PhD, Chief Scientific Officer at Opexa.
“The goals of this program are to further understand the biology behind
the mechanism of action for Tcelna and to possibly identify novel
biomarkers that are dominant in the pathophysiology of SPMS patients.
The program encompasses an analysis of various pro-inflammatory and
anti-inflammatory biomarkers. We believe that the blinded data, which
will be analyzed during the course of the trial, may potentially signal
responders and non-responders when correlated with clinical data on
completion of the Abili-T study.”
The article can be accessed here
or from the home and investor relations pages of Opexa’s website.
Neurology Reviews covers innovative and emerging news in
neurology and neuroscience every month, with a focus on clinical
research and practical approaches to treating Parkinson’s disease,
epilepsy, headache, stroke, multiple sclerosis, Alzheimer’s disease, and
other neurologic disorders.